From the Pediatric Nephrology Department, Charles Nicolle Hospital and the University of Tunis El Manar, Faculty of Medicine of Tunis, Tunis, Tunisia.
Exp Clin Transplant. 2024 Jan;22(Suppl 1):110-117. doi: 10.6002/ect.MESOT2023.O20.
We aimed to identify risk factors and outcomes of delayed graft function in pediatric kidney transplant.
This retrospective study included all kidney transplant recipients ≤19 years old followed up in our department for a period of 34 years, from January 1989 to December 2022.
We included 113 kidney transplant recipients. Delayed graft function occurred in 17 cases (15%). Posttransplant red blood cell transfusion was strongly associated with delayed graft function (adjusted odds ratio = 23.91; 95% CI, 2.889-197.915). Use of allografts with multiple arteries and cold ischemia time >20 hours were risk factors for delayed graft function (adjusted odds ratio = 52.51 and 49.4; 95% CI, 2.576-1070.407 and 1.833-1334.204, respectively). Sex-matched transplants and living donors were protective factors for delayed graft function (adjusted odds ratio = 0.043 and 0.027; 95% CI, 0.005-0.344 and 0.003-0.247, respectively). Total HLA mismatches <3 played a protective role for delayed graft function (adjusted odds ratio = 0.114; 95% CI, 0.020-0.662), whereas transplant within compatible but different blood types increased the risk of delayed graft function (adjusted odds ratio = 20.54; 95% CI, 1.960- 215.263). No significant correlation was shown between delayed graft function and allograft survival (P = .190). Our study suggested delayed graft function as a key factor in allograft rejection-free survival (adjusted odds ratio = 3.832; 95% CI, 1.186-12.377). Delayed graft function was a negative factor for early graft function; patients with delayed graft function had a lower estimated glomerular filtration rate at discharge (P = .024) and at 3 (P = .034), 6 (P = .019), and 12 months (P = .011) posttransplant.
Delayed graft function is a major determinant of early graft function and allograft rejection-free survival. Further research is required to establish proper preventive measures.
我们旨在确定儿科肾移植中延迟移植物功能的风险因素和结果。
本回顾性研究纳入了 19 岁以下在我科接受随访的所有肾移植受者,随访时间为 34 年,从 1989 年 1 月至 2022 年 12 月。
我们纳入了 113 例肾移植受者。17 例(15%)发生了延迟移植物功能。移植后红细胞输注与延迟移植物功能密切相关(调整后优势比=23.91;95%可信区间,2.889-197.915)。使用具有多动脉的同种异体移植物和冷缺血时间>20 小时是延迟移植物功能的危险因素(调整后优势比=52.51 和 49.4;95%可信区间,2.576-1070.407 和 1.833-1334.204)。性别匹配的移植和活体供者是延迟移植物功能的保护因素(调整后优势比=0.043 和 0.027;95%可信区间,0.005-0.344 和 0.003-0.247)。总 HLA 错配<3 对延迟移植物功能有保护作用(调整后优势比=0.114;95%可信区间,0.020-0.662),而在相容但不同血型之间进行移植会增加延迟移植物功能的风险(调整后优势比=20.54;95%可信区间,1.960-215.263)。延迟移植物功能与同种异体移植物存活率之间无显著相关性(P=.190)。我们的研究表明,延迟移植物功能是同种异体移植物无排斥存活的关键因素(调整后优势比=3.832;95%可信区间,1.186-12.377)。延迟移植物功能是早期移植物功能的一个负面因素;延迟移植物功能的患者在出院时(P=.024)、移植后 3 个月(P=.034)、6 个月(P=.019)和 12 个月(P=.011)时肾小球滤过率估计值较低。
延迟移植物功能是早期移植物功能和同种异体移植物无排斥存活的主要决定因素。需要进一步研究以确定适当的预防措施。